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Levels of human immunodeficiency virus (HIV) DNA, RNA, or p24 antigen and reverse transcriptase activity
in T-cell cultures treated with 500 IU of recombinant alpha interferon (rIFNa) per ml were comparable to those
in control cultures. Radioimmunoprecipitation analysis of proteins in lysates of IFN-treated T cells documented
a marked accumulation of HlV proteins. Localization of gp120 by immunofluorescence showed a diffuse
pattern in IFN-treated cells quite distinct from the ring pattern in untreated control cells. That large quantities
of a 1 2 0 in aberrant cell compartments might affect HlV morphogenesis was confirmed in infectivity studies:
virions from IFN-treated cells were 100- to 1,000-fold less infectious than an equal number of virions from
control cells. Direct examination of IFN-treated and control HW-infected cells by transmission electron
microscopy showed little difference in the number or distribution of viral particles. However, quantitation of
a 1 2 0 by immunogold particle analysis revealed a marked depletion of envelope glycoprotein in virions released
from IFN-treated cells. This defect in gp120 assembly onto mature viral particles provides a molecular basis for
this loss of infectivity.
Clinical and experimental observations support a central
role for alpha interferon (IFN-a) in the regulation of human
immunodeficiency virus (HIV) replication (2, 5-7, 9-11,
1 6 1 6 , 23, 25, 26, 28, 31, 32, 34, 35). High-titer viremia with
HIV present in both plasma and cells is evident during acute
infection. Within weeks of the onset of symptoms, HIV
viremia falls to low levels. IFN levels in plasma directly
correlate with viral load during this acute viral syndrome (32,
35). Clinical trials of exogenous IFN-a in early HIV disease
show a significant reduction in the level of p24 antigen (Ag)
in the plasma of treated subjects and less AIDS-associated
opportunistic infection (15). Such preliminary evidence for
antiviral efficacy in patients is matched by other reports that
document the potent antiviral activity of IFN in HIVinfected T-cell and monocyte cultures (7, 9, 10, 14, 23, 25,
30). HIV infection of monocytes is completely inhibited by
IFN-a administered prior to or at the time of viral challenge
(9, 14). HIV-infected monocytes treated with IFN-a after
infection show little or no viral gene expression. However,
and in contrast to the antiviral effects seen in monocytes, the
effects of IFN-a on HIV replication in T cells are less
dramatic (7, 9, 25, 30, 33, 34). A number of studies show no
changes in viral gene expression following IFN-treatment of
HIV-infected T cells. Although most investigators agree that
the principal effect of IFN in T cells is on the terminal stage
of the HIV life cycle, there is little accord as to the exact
nature of this effect (7, 9, 23, 25, 30, 33). We describe in this
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report an IFN-associated defect in the assembly of gp120
onto mature viral particles that accounts for significant loss
of virion infectivity. This assembly defect provides a novel
molecular basis for IFN-associated antiviral effects on HIV
replication in T cells.
To measure the effect of IFN-a on levels of HIV DNA and
RNA in infected T cells, peripheral blood mononuclear cells
isolated from whole blood by Ficoll-diatrizoate density gradient centrifugation were cultured in RPMI 1640 (GIBCO,
Grand Island, N.Y.) with 1 kg of phytohemagglutinin (PHA;
Sigma Chemical Co., St. Louis, Mo.) per ml, 10% partially
purified human interleukin-2 (IL-2; Advanced Biotechnologies Inc., Col'umbia, Md.), and 15% heat-inactivated fetal
calf serum (Sterile Systems, Inc., Logan, Utah) for 3 days.
P W L - 2 - t r e a t e d T cells were exposed to HIV-l,,~,,,,
(Advanced Biotechnologies) at a multiplicity of infection of
0.01 infectious virus per target cell with and without 500 IU
of rIFN-a,, per ml (a generous gift from Schering-Plough
Research Laboratories, Inc., Kenilworth, N.J.). All virus
stock and reagents were free of mycoplasma (Gen-probe 11;
Gen-probe Inc., San Diego, Calif.) and bacterial endotoxin
contamination. Culture medium was half exchanged every 2
to 3 days for 2 weeks. Cell lysates of HIV-infected T cells
were extracted with phenol and chloroform-isoamyl alcohol,
and the DNA was precipitated with ethanol. Polymerase
chain reaction amplification of HIV-specific DNA sequences
with nucleotide primers from the 5' long terminal repeat and
gag genes and 2.5 U of Tag polymerase (Cetus Corp.,
Emeryville, Calif.) per ml was performed on 1 kg of total
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TABLE 1. Effect of IFN-a on levels of HIV p24 Ag and RT
activity in culture fluids and lysates of infected T cellsa

Culture fraction

~-

Control
cells

HlVgag DNA

RT activity (%)
(1@
. c~m/ml)
. , in:

Level (%) of p24 Ag
{nn/ml), in:
Cells with
IFN-u

Control
cells

Cells with
IFN-a

-

IFN a A

Culture fluids
Cell lysate

78 (90%)
9 (10%)

67 (76%)
21 (24%)

34.4 (96%)
1.3 (4%)

27.3 (84%)
5.2 (16%)

Total

87

88

35.7

32.5

-

" PWLZ-treated T cells infected with HIV-I,,.,,,,

GAPDH 1

"

?';'**

FIG. 1. Effect of IFN-a on levels of HIV DNA and RNA in
14-day HIV-l,nv.,IIB-infected T cells. HIV g a g DNA was amplified by the polymerase chain reaction. Levels of DNA for the
IFN-a, gene in cell lysates served as a reference for comparison
between samples. HIVgag RNAwas subjected to reverse transcription and polymerase chain reaction amplification of the cDNA
transcripts. mRNA for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal reference to allow analysis of
RNA between different samples.

cellular DNA with an automatic cycler (Perkin Elmer-Cetus,
Emeryville, Calif.). The products of 25 cycles were analyzed
by Southern blot hybridization after agarose gel electrophoresis with a radiolabeled DNA probe specific for a gag
sequence internal to the primer pairs. Levels of DNA for the
IFN-a* gene in cell lysates served as a reference for
comparisons between samples (9). Total RNA was extracted
from cell lysates with acidic guanidinium isothiocyanatephenol-chloroform. Levels of viral and cellular RNA were
estimated after reverse transcription with antisense primers
and polymerase chain reaction amplification of the cDNA
transcripts. The mRNA for the cellular enzyme, glyceraldehyde 3-phosphate dehydrogenase served as internal reference to allow analysis of RNA between different samples.
Initial studies showed that HIV-1 replication in T cells was
only minimally affected by exposure to recombinant IFN-a
(rIFN-a). We and others show that even concentrations of
rIFN-a as high as 10,000 IU/ml will not prevent infection of
primary T cells or T-cell lines by HIV (9, 30, 33). Furthermore, levels of HIV DNA and RNA in 14-day HIV-1infected T cells treated with 500 IU of rIFN-a per ml at the
time of infection and throughout 2 weeks of culture were no
different from those in untreated control cells (Fig. 1).
Similarly, levels of p24 Ag and reverse transcriptase (RT)
activity in the same cultures are comparable (<twofold
difference). Levels of p24 Ag and RT activity in T-cell
cultures treated with 500 IU of rIFNa per ml were 89% + 2%
and 74% 2 6% (mean 2 standard error of the mean [SEMI
for three different experiments), respectively, of those in
control cultures 12 to 15 days after HIV infection.
More detailed analysis of p24 Ag and RT activity levels in
IFN-treated cells revealed a marked difference in the localization of these viral proteins (Table 1). Less than 10% of p24
Ag in cultures of HIV-infected T cells was found in cell
lysates 2 weeks after infection (7% 2 3% [mean 2 SEM for
three experiments]). In contrast, levels of p24 Ag in lysates
of HIV-infected T cells treated continuously with rIFN-a for

were cultured with
and without 500 IU of rIFNa per ml for 2 weeks. Levels of p24 Ag in culture
fluids and freeze-thaw cell lysateswere determined in triplicate by enzyme-lied
immunosorbent assay (E. I. Du Pont de Nemours & Co., Biierica, Mass.). RT
activity was estimated by incorporation of ['HIdTP into DNA transcripts of
polyr(A) (9). Radioactivity was estimated by liquid scintillation spectroscopy.
HIV-1 stock served as positive control for p24 Ag and RT activity.

2 weeks were 24% of the total p24 Ag level in these cultures
(23% 2 1% [mean 2 SEM for three experiments]). Indeed,
although there was no difference in total p24 Ag levels
between IFN-treated and control cells, the level of cell-

FIG. 2. Effect of IFN-a on levels of HIV proteins in infected T
were
cells. PHAnL-2-treated T cells infected with HIV-l,v,IIB
cultured with and without 0 to 500 IU of rIFN-a Der ml for 2 weeks.
All cultures were exposed to 250 kCi of ["~]meihionine for 3 h and
then washed. Radiolabeled HIV-s~ecific rote ins were isolated from
cell lysates with pooled HIV-s&opositjve sera bound to protein
~ - s e p h a r o s eCL-4s (Phannacia). he immune complexeg were
washed and boiled; immunoprecipitated proteins were analyzed by
sodium dodecyl sulfate-pol~acryfamidegel electrophoresis-and a i toradiography (1, 32).

NOTES

7545

FIG. 3. Effect of I F N a on the distribution of gpl20 in HIV-infected T cells. PHML-2-treated T cells infected with HIV-l,v~II,B were
cultured with and without 500 IU of rIFN-a per ml for 2 weeks. Cells were washed, fixed in acetone, and exposed to goat anti-HIV-l,, gp120
(12)(provided by N. Haigwood, Chiron Corp.). Treated cells were washed after a reaction time of 1h on ice and then resuspended for another
1h in fluorescein isothiocyanate-conjugated rabbit anti-goat immunoglobulin G (Sigma). Washed cells were examined by epi-illumination
fluorescence microscopy (18). (A) Uninfected control cells. (B and C) HIV-infected T cells cultured with (panel C) and without (panel B)
IFN-a. Magnification, x250.
associated p24 Ag in IFN-treated cultures was threefold
higher than that in control cultures. Localization of RT
activity in cultures of IFN-treated cells followed a similar
pattern. Again, only 3% of RT activity in cultures of HIV-

i control

?'

HIV (relative concentration)

FIG. 4. Effect of IFN on infectivity of progeny virus from HIVinfected primary T cells. PWCZtreated T cells infected with
HIV-l,
at a multiplicity of infection of 1were cultured with and
without 500 IU of r1FN-a per ml. Seven days after infection, virus in
fluids of control and IFN-treated cultures was pelleted by ultracentrifugation and adjusted to equal levels of RT activity. Fourfold viral
dilutionswere added to uninfected PWG2-treated T cells. Levels of
RT activity in culture fluids (mean of triplicate determinations) are
shown 10 days after infection. The SEM for the triplicate determinations for each point was less than 10%of the mean value.

infected T cells was found in cell lysates 2 weeks after
infection (3% + 1% [mean 2 SEM for three experiments]).
Most RT activity was released into the culture fluid. Virtually all of this RT activity was virion associated and was
recovered in the pellet after ultracentrifugation. Levels of
RT activity in lysates of T cells treated continuously with
rIFN-or for 2 weeks were 15% of the total RT activity in these
cultures (15% + 1% [mean 2 SEM for three experiments]).
Cell-associated RT activity in IFN-treated cultures was fourto fivefold higher than that in control cultures.
The preceding data documented an accumulation of viral
proteins and virions within IFN-treated T cells. This accumulation was confirmed by radioimmunoprecipitation analysis of viral proteins in cell lysates 2 weeks after infection
(Fig. 2). The total amount of HIV protein in lysates of
IFN-treated cells increased directly with the IFN concentration. It is important to note that processing of HIV proteins
(relative levels of gp160 and gp120 or p55 and p24) in
IFN-treated and control cells at this level of analysis was
comparable (Fig. 2).
Further evidence that IFN treatment of infected T cells
induced accumulation of viral proteins within the cell is
strikingly illustrated in immunofluorescence studies for
gp120 (Fig. 3). HIV-infected T cells showed a characteristic
ring pattern for gp120; virtually all of this processed HIV
envelope glycoprotein was at or on the plasma membrane. In
contrast, the identical cells treated continuously with IFN
for 2 weeks showed a bright and diffuse pattern for gp120.
Previous reports show that about 10% of gp160 in T cells is
cleaved to produce gp120. Most gp160 (85 to 95%) is
transported to and degraded in lysosomes (32). In the
absence of IFN treatment, gp120 is transported to the
plasma membrane without degradation and assembled into
mature virions. IFN treatment markedly affects this transport process by mechanisms presently unknown, so that
gp120 or unprocessed gp160 becomes diffusely localized
throughout the cell. Interestingly, radioimmunoprecipitation
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FIG. 5. Effect of IFN-u on envelope gp120 of virions from HIV-infected H9 cells. H9 cells (provided by R. C. Gallo, National Institutes
of Health) infected with HIV-l,,.,,,,
were cultured with and without 500 IU of rIFN-u per ml for 2 weeks and then exposed to goat
anti-HIV-l,, gp120 (12) for 2 h at room temperature. Antibody-treated cells were washed and exposed to rabbit anti-goat immunoglobulin
G-gold conjugate (10-nm gold particles; Amersham International, Amersham, United Kingdom) for 2 h at room temperature. Unbound gold
particles were removed after washing. Cells were lixed in 2.5% glutaraldehyde, postlixed in 1% osmium tetroxide, en block stained,
dehydrated in ethanol, and embedded in SPURR's plastic resin. After polymerization, blocks were cut, and 50- to 70-nm sections were placed
on copper grids and poststained with lead citrate (22). Grids were examined in a JEOL l00B electron microscope. (A) Virions from control
HIV-infected H9 cells. (B) Virions from IFN-treated cells. Magnification, ~73,000.

analysis showed that the relative amounts of gp160 and
a 1 2 0 were not changed by IFN treatment. This suggests
that gp120 is not degraded in its altered cellular compartment.
Accumulation of a 1 2 0 in alternative cell compartments
during IFN treatment suggested that this envelope component may not be freely available for virus assembly. We
examined this hypothesis by performing a direct analysis of
virions released from IFN-treated T cells. Progeny virions in
culture fluids of IFN-treated and control cells 2 weeks after
virus infection were adjusted to equal levels of RT activity

and assayed for infectivity on PHA/IL-2-treated T cells (Fig.
4). Virions from IFN-treated cells were at least 1,000-fold
less infectious than an equal number of virions from control
cells. Such loss of infectivity was confirmed in three replicate experiments and in a syncytial plaque assay with
CEM-SS cells (20). Again, virions from IFN-treated cells
were 100- to 1,000-fold less infectious than an equal number
of virions from control cells.
The most direct evidence that virions from IFN-treated T
cells were deficient in envelope a 1 2 0 came from transmission electron-microscopic studies with immunogold-labeled

NOTES

anti-gpl20 (Fig. 5). HIV virions were numerous at the
plasma membrane 12 days after virus infection. The immunogold label delineated obvious virion-associated gp120 on
most viral particles. In a survey of 225 individual virions, the
average number of gold particles per virion was 5.5 2 0.4
(mean 2 SEM). In contrast, virions from the identical cells
treated continuously with IFN showed a marked reduction
in the amount of gp120. There was no appreciable change in
the number or distribution of virions at the plasma membrane of IFN-treated cells, but the number of gold particles
per virion was 0.5 ? 0.1 (mean + SEM for 122 virions), a
reduction of 91%. A replicate experiment showed 10.5 gold
particles per virion with control T cells 11 days after HIV
infection versus 0.9 gold particles per virion (a reduction of
91%) from the same cells treated with 500 IU of rIFN-a per
ml. Experiments with H9 cells, a continuous T-cell line,
infected with HIV-l,,~,,,,
and cultured with and without
rIFN-or for 10 days showed changes in virion-associated
gp120 of similar magnitude. The number of gold particles per
virion in cultures of H9 cells was 1.4 + 0.2 (mean 2 SEM for
140 virions). Virions from IFN-treated H9 cells had only 0.2
2 0.1 gold particle per virion (mean 2 SEM for 82 virions),
a reduction of 86%. Another experiment with H9 cells
showed 4.5 gold particles per virion in control cells 8 days
after HIV infection versus 0.7 gold particle per virion (a
reduction of 85%) in cells treated with 500 IU of rIFN-a per
ml. These studies document a profound and selective depletion of HIV envelope gp120 on the virions released from
IFN-treated infected T cells and provide a molecular basis
for the loss of infectivity.
A major antiviral effect of IFN for inhibition of HIV
replication in T cells operates in the stages of virus assembly
and release (30,33). There is general agreement that the rate
and extent of viral protein synthesis change little during IFN
treatment of chemically HIV-infected T cells (7, 9, 30, 33).
Other antiviral effects of rIFN-a were demonstrated during
acute infection of T cells with HIV-1 (12a, 28). However, the
numbers of progeny virus released from infected cells are
reproducibly decreased for both primary T cells from blood
and continuous T-cell lines (7, 9, 28, 30, 33). Certain investigators find decreased numbers of virions budding into
extracellular spaces (30); others report a marked accumulation of viral particles at the cell surface (33). We confirm this
effect of IFN on HIV replication in T cells. Synthesis of HIV
DNA, RNA, and protein was minimally affected, even by
high concentrations of IFN administered continuously
throughout the culture interval. Indeed, the morphology and
number of virions at the plasma membrane in IFN-treated
and control HIV-infected cells were indistinguishable by
transmission electron microscopy. However, these analyses
underestimate the potent effects of IFN on HIV morphogenesis. Virions released from IFN-treated T cells were 100- to
1,000-fold less infectious than an equal number of virions
from control cells. The basis for this dramatic change resides
in an assembly defect for gp120 onto the mature viral
particle.
The effects of IFN on HIV morphogenesis in T cells has
precedent in other viral systems (8, 17-19, 24). Progeny
vesicular stomatitis virus (a rhabdovirus) and murine leukemia virus (a retrovirus) from infected cells treated with
IFN-a are much less infectious than are virions from control
cells (3, 13, 17-19, 21, 24,27, 29). Analysis of progeny virus
from IFN-treated vesicular stomatitis virus-infected cells by
transmission electron microscopy documents a marked decrease in glywprotein envelope spikes (17-19). Transport of
the vesicular stomatitis virus envelope glycoprotein to the
- -
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plasma membrane is inhibited by IFN-a. Immunofluorescence studies show accumulation of envelope glycoprotein
in Golgi complexes: endoglycosidase digestion experiments
suggest an IFN-a-associated block in envelope glycoprotein
transport through the trans Golgi (4, 29). Similarly, changes
in the infectivity of murine leukemia viruses are directly
related to IFN-a-induced alterations of viral envelope glycoprotein processing and assembly (3). These fundamental
observations provide a sound basis for exploration of IFNassociated defects in gp120 assembly in HIV-infected T
cells. Studies directed at mechanisms of gp160 cleavage,
transport of gp120 through the Golgi complex, and assembly
of gp120 onto the core virion at or near the plasma membrane are directed at key areas of investigation. Careful
definition of the site and mechanism of IFN action should
allow better design of alternate therapeutic agents that act at
this vulnerable stage of the HIV life cycle.
We thank Robert M. Friedman, Uniformed Services University of
the Health Sciences, and James E. Whitman, Jr., for helpful
discussions and Victoria Hunter for excellent graphics.
H. E. Gendelman is a Carter-Wallace Fellow of the Johns
Hopkins University School of Public Health and Hygiene in the
Department of Immunology and Infectious Diseases. This work was
supported in part by the Henry M. Jackson Foundation for the
Advancement of Military Medicine.
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